Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis
Update: 2025-10-30
Description
Featuring an interview from Dr John Strickler, including the following topics:
- Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00 )
- Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09 )
- Tumor-informed MRD assays under clinical development (20:36 )
- Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19 )
- Case: A man in his late 50s with resected Stage IIA colon cancer (30:06 )
- Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57 )
- MRD as a future clinical trial endpoint for solid tumors; increasing incidence of colorectal cancer in younger people (40:24 )
- Antibody-drug conjugates in the treatment of colorectal cancer (45:13 )
- Perspectives on promising areas of clinical research in colorectal cancer (48:23 )
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
